# Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

> **NCT06176690** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 90 (estimated)

## Conditions studied

- CD30-Positive Diffuse Large B-Cell Lymphoma
- Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Peripheral T-cell Lymphoma
- Anaplastic Large Cell Lymphoma, ALK-negative
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** C7R.CD30.CAR-EBVST cells

## Key facts

- **NCT ID:** NCT06176690
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2028-07-27
- **Final completion:** 2043-06-27
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176690, "Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06176690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*